Evidence map›Paper›PMID 41031161›Full record

ReviewFrontiers in pharmacology2025

Wenru Wang, Jixin Li, Yan Yan, Qin Zeng, Lei Yan, Xinhui Wang, Ying Liang, Renhuan Yu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wenru Wang *Department of Nephrology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China.
Jixin Li *Department of Nephrology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China.
Yan YanHubei University of Chinese Medicine, Wuhan, China.
Qin ZengZhujiang Hospital, Southern Medical University, Guangzhou, China.
Lei YanDepartment of Nephrology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China.
Xinhui WangDepartment of Nephrology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China.
Ying LiangDepartment of Nephrology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China.
Renhuan YuDepartment of Nephrology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetic kidney disease (DKD) is a common microvascular complication of diabetes. With the continuous rise in the prevalence of diabetes, it has become the primary cause of end-stage renal disease. Currently, there are no effective clinical treatments available to reverse the progression of DKD.

Indexed as

active compoundsChinese herbal medicinediabetic kidney diseasemechanismStephania tetrandra S. Moore

Identifiers

PMID41031161
PMCPMC12477166

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.